Follicular Lymphoma Clinical Trials

456 clinical trials for Follicular Lymphoma across international registries, including 118 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) — RECRUITING · PHASE2
• Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL — RECRUITING · PHASE2
• Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies — RECRUITING · PHASE1
• A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma — RECRUITING · PHASE3
• HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL — RECRUITING · PHASE2
• AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas — RECRUITING · PHASE1
• Trial to Evaluate Efficacy and Safety of Subcutaneous Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma . — RECRUITING · PHASE2
• A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma — RECRUITING · PHASE2
• A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma — RECRUITING · PHASE3
• A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies — RECRUITING · PHASE1
• A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers — RECRUITING · PHASE1
• Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) — RECRUITING · PHASE1
• LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies — RECRUITING · PHASE1
• Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) — RECRUITING
• A Long-term Extension Study of PCI-32765 (Ibrutinib) — RECRUITING · PHASE3
• A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies — RECRUITING · PHASE1
• IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas — RECRUITING · PHASE1
• A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma — RECRUITING · PHASE1
• This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Clonal Evolution in Follicular Lymphoma — RECRUITING
• A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies — RECRUITING
• Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms — RECRUITING
• Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma — RECRUITING
• Allo HSCT Using RIC and PTCy for Hematological Diseases — RECRUITING · PHASE2
• A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies — RECRUITING · PHASE1
• Combating Cancer-Related Fatigue: A Personalized Supportive Care Program — RECRUITING · NA
• Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders — RECRUITING · PHASE2
• Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Evaluation of Skin Tests in Biotherapy Allergies — RECRUITING · NA
• 64Cu-LLP2A for Imaging Hematologic Malignancies — RECRUITING · PHASE1
• A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies — RECRUITING · PHASE1
• Long-term Study to Evaluate Safety and Persistence of GF-CART01 — RECRUITING
• Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma — RECRUITING · PHASE2
• Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 — RECRUITING · PHASE3
• Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution — RECRUITING
• Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi — RECRUITING · PHASE3
• Epcoritamab and Rituximab for First-line Follicular Lymphoma — RECRUITING · PHASE2
• A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) — RECRUITING · PHASE3
• Prognostic and predictive cytogenetic variants in hematological neoplasia — RECRUITING
• Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma — RECRUITING · PHASE2
• CD70-targeted immunoPET Imaging of Malignant Cancers — RECRUITING · PHASE2
• Prospective Examination on Neurocognitive Outcomes Following Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy — RECRUITING
• A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma — RECRUITING · PHASE2
• Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma — RECRUITING · PHASE1
• A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma — RECRUITING · PHASE1
• Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) — RECRUITING · PHASE2
• Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader — RECRUITING · PHASE1
• Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma — RECRUITING · PHASE1
• SynKIR-310 for Relapsed/Refractory B-NHL — RECRUITING · PHASE1
• German Registry for Marginal Zone Lymphoma and Follicular Lymphoma — RECRUITING

Refine this search